References

  1. Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews 2012;(2):CD004407. DOI: 10.1002/14651858.CD004407.pub3.
  2. National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook. 9th ed. Canberra: Australian Government Department of Health and Ageing; 2008.
  3. Eldred BE, Dean AJ, McGuire TM, Nash AL. Vaccine components and constituents: responding to consumer concerns. Medical Journal of Australia 2006; 184: 170-5.
  4. Hutchins SS, Bellini WJ, Coronado V, et al. Population immunity to measles in the United States, 1999. J Infect Dis 2004;189 Suppl 1:S91-7.
  5. Kurry PK, Kruszon-Moran DM, Dayan GH, et al. Seroprevalence of antibody to mumps virus in the US population, 1999-2004. J Infect Dis. 2010;202(5):667-74
  6. Hyde TB, Kruszon-Moran D, McQuillan GM, et al. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis. 2006;43 Suppl 3:S146-50
  7. Perry RT, Halsey NA. The clinical significance of measles: a review. Journal of Infectious Diseases 2004; 189: S4-S16.
  8. Offit PA, Quarles J, Gerber MA, Hackett CJ, Marcuse EK, Kollman TR, et al. Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics 2002; 109: 124-9.
  9. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-41.
  10. Retraction - Ileal-lymphoid-nodular hyperplasia, non-specific colitis and pervasive developmental disorder in children. Lancet 2010; 375: 445.
  11. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology & Psychiatry & Allied Disciplines 2005; 46: 572-9.
  12. Madsen KM, Vestergaard M. MMR vaccination and autism: what is the evidence for a causal association?Drug Safety 2004; 27: 831-40.
  13. Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism & Developmental Disorders 2007; 37: 210-7.
  14. Medicare Australia. Australian Childhood Immunisation Register (ACIR) Statistics. 2012. Available at: http://www.medicareaustralia.gov.au/provider/patients/acir/statistics.shtml. Accessed December 2012.
  15. World Health Organization, Regional Office for the Western Pacific Expanded Programme on Immunization. Measles bulletin. 2004; (2): 2. Available at:
    http://www.wpro.who.int/NR/rdonlyres/5A88F886-E331-49D1-A0EA-2BF9BFD517EF/0/MeasBulletin2004Q2.pdf. Accessed December 2012.
  16. Fielding JE, Outbreak Investigation Team. An outbreak of measles in Adelaide. Communicable Diseases Intelligence 2005; 29: 80-2.
  17. Brotherton J, Wang H, Schaffer A, Quinn H, Menzies R, Hull B, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Communicable Diseases Intelligence 2007; 31(Suppl): viii-S152.
  18. Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia: Saunders Elsevier; 2008.
  19. Mantadakis E, Farmaki E, Buchanan GR. (2010) Thrombocytopenic purpura after measles–mumps–rubella vaccination: a systematic review of the literature and guidance for management. Journal of Pediatrics 2010; 156: 623–8.
  20. Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, Zaki SR, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. Journal of Infectious Diseases 2005; 192: 1686-93.


Copyright NCIRS 2009 - Last updated 14 July 2015